Improved Treatment on Ocular Inflammation with Rationally Designed Thermoresponsive Nanocomposite Formulation. Issue 10 (28th July 2021)

• Record Type: Journal Article
• Authors: Zhang, Shaohua; Fang, Yanwen; Sun, Jianguo; Deng, Yonghui; Lu, Yi
• Is Part Of: Advanced therapeutics. Volume 4:Issue 10(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-07-28
• Subjects: levofloxacin -- mesoporous silica nanoparticles -- ocular inflammation -- prednisolone acetate -- thermoresponsive nanocomposite formulation; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202100088
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Cataract is the principal cause of preventable blindness in older people globally. Intraocular surgeries stimulate multiple postoperative inflammatory responses. The current clinical treatment by dropping prednisolone acetate (PA) and levofloxacin (LF) suffers from drawbacks, such as low bioavailability and poor patient compliance. This study aims to develop a rationally designed thermoresponsive formulation combining PA and LF using nancomposites of mesoporous silica nanoparticle (MSN) and thermo‐nanogel (thermogel) (PA@MSN‐LF@Thermogel). The in vitro release profiles of PA and LF from PA@MSN‐LF@Thermogel are tailor‐made to adapt to wound healing by a sustained release of 28 days. PA@MSN‐LF@Thermogel exhibits little cytotoxicity to human Tenon's fibroblasts and human corneal epithelial cells, while presents excellent in vitro antibacterial effectiveness to Staphylococcus bacteria. After implanted into the rabbit eye by a subconjunctival injection, PA@MSN‐LF@Thermogel displays overwhelming anti‐inflammatory and antibacterial effectiveness up to 21 days using only one‐eighth of the total dose, compared with PA and LF eye drops. The formulation does not cause any ocular hypertension and noticeable histopathological abnormality which indicate good biosafety. This thermoresponsive nanocomposite formulation is thus a promising drug delivery alternative for treatment of postoperative inflammation after intraocular surgeries. Abstract : A novel thermoresponsive nanocomposite formulation made of prednisolone acetate (PA)‐loaded mesoporous silica nanoparticles (PA@MSN) in thermo‐nanogel matrix with levofloxacin (LF) (PA@MSN‐LF@Thermogel) is developed to treat ocular inflammation by a sustained and regulated release for 21 days. PA@MSN‐LF@Thermogel synergistically improves ocular inflammation treatment through anti‐inflammatory and antibacterial effectiveness in a rabbit model.